Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Treatment Choice Clear all
Completed Phase 1 Interventional

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

NCT01625351
View directory record Official record
Conditions
Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic Tumor, Lymphoma, Wilms Tumor, Rhabdoid Tumor, Clear Cell Carcinoma, Renal Cell Carcinoma, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma
Interventions
alemtuzumab, fludarabine, sirolimus, Busulfan, melphalan, stem cells, CliniMACS
Drug · Biological · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 23, 2026, 5:28 PM EDT
Completed No phase listed Observational

Optimizing Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke

NCT02446587
View directory record Official record
Conditions
Stroke, Ischemic Stroke
Interventions
Mechanical Thrombectomy
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
9
States / cities
Stanford, California • Orlando, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 23, 2026, 5:28 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)

NCT05606614
View directory record Official record
Conditions
Rett Syndrome
Interventions
TSHA-102
Genetic
Lead sponsor
Taysha Gene Therapies, Inc.
Industry
Eligibility
6 Years to 21 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
8
States / cities
Duarte, California • La Jolla, California • Oakland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 23, 2026, 5:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Aerobic Exercise and Cognitive Training Effects on Postconcussive Symptomology

NCT03674398
View directory record Official record
Conditions
Post-Concussion Syndrome, Post-Traumatic Headache, Post-Concussive Syndrome, Chronic, Head Injury, MTBI - Mild Traumatic Brain Injury, Acquired Brain Injury, Closed Head Injury
Interventions
Exercise+CT, Exercise only
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 23, 2026, 5:28 PM EDT
Terminated Not applicable Interventional

Tolvaptan for Patients With Acute Neurological Injuries

NCT02545114
View directory record Official record
Conditions
Hyponatremia, SIADH
Interventions
Tolvaptan
Drug
Lead sponsor
Polderman, Kees, H., MD, PhD
Individual
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2018 · Synced Sep 23, 2026, 5:28 PM EDT
Completed No phase listed Observational

Therapeutic Peri-implant Maintenance with Laser Therapy

NCT04251793
View directory record Official record
Conditions
Peri-Implantitis
Interventions
Observation
Other
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 23, 2026, 5:28 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

NCT03376321
View directory record Official record
Conditions
Influenza A
Interventions
Pimodivir 600 mg, Placebo, SOC Treatment
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
13 Years to 85 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 23, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

NCT03170544
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Placebo to glargine, Placebo to MK-1092, Dextrose, Insulin
Drug · Other · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 23, 2026, 5:28 PM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Faces: Choices Study

NCT02409862
View directory record Official record
Conditions
Socioemotional Aging
Interventions
Oxytocin Spray, Placebo Spray
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 25, 2018 · Synced Sep 23, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Results available

Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer

NCT02215096
View directory record Official record
Conditions
Neoplasms
Interventions
GSK2636771, Enzalutamide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
7
States / cities
Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 23, 2026, 5:28 PM EDT
Completed No phase listed Observational

Rational Therapeutics Based on Matched Tumor and Normal Tissue

NCT02272595
View directory record Official record
Conditions
Advanced Cancers
Interventions
Treatment Based on Genetic Mutation, Treatment Based on No Genetic Mutation
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Sep 23, 2026, 5:28 PM EDT
Completed Phase 2Phase 3 Interventional

The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder

NCT04318639
View directory record Official record
Conditions
Alcohol Use Disorder, Mild Cognitive Impairment
Interventions
Donepazil
Combination Product
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
21 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Sep 23, 2026, 5:28 PM EDT
Completed Not applicable Interventional

PTSD Mobile App for Cancer Survivors

NCT04058795
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Cancer
Interventions
Cancer Distress Coach (CaDC) App, CaDC + mCoaching, mCBT
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 85 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Sep 23, 2026, 5:28 PM EDT
Recruiting Phase 1 Interventional

ORB-021 In Patients With Advanced Solid Tumors

NCT06607939
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
ORB-021
Drug
Lead sponsor
Orionis Biosciences Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Scottsdale, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 23, 2026, 5:28 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dextenza With ILUX for Treatment of MGD

NCT04658927
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Evaporative Dry Eye
Interventions
Dexamethasone, 0.4mg, Prednisone acetate, Control
Drug · Other
Lead sponsor
Warrenville Eyecare
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 23, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients

NCT00621361
View directory record Official record
Conditions
Lung Cancer
Interventions
AZD2171, Etoposide, Cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Sacramento, California • Denver, Colorado • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Sep 23, 2026, 5:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users

NCT01612169
View directory record Official record
Conditions
HIV, AIDS, Substance Abuse, Inpatient
Interventions
Patient Navigation (PN) Group, Patient Navigator Plus Contingency Management (PN+CM) Group
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
801 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
12
States / cities
Birmingham, Alabama • Torrance, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 23, 2026, 5:28 PM EDT
Recruiting Not applicable Interventional

Effect of BFR Rehab After Achilles Tendon Rupture

NCT06254794
View directory record Official record
Conditions
Achilles Tendon Rupture
Interventions
Blood flow restriction with Delfi Personalized Tourniquet System (PTS), Physical therapy
Device · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 23, 2026, 5:28 PM EDT
Completed Not applicable Interventional

Coping Peer Intervention for Adherence

NCT01169883
View directory record Official record
Conditions
Asthma
Interventions
Coping Peer Support, Doctor Asthma Messages, Coping Peer Asthma Messages, Asthma Supervision, Music Tracks
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
11 Years to 16 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Sep 23, 2026, 5:28 PM EDT
Enrolling by invitation Not applicable Interventional

Evaluating the Effect of Automatic Plan Assignment and Enhanced Outreach of Marketplace Take-up

NCT06709794
View directory record Official record
Conditions
Outreach Intervention
Interventions
Informational flyer, Modified eligibility notice with plan information
Behavioral
Lead sponsor
Covered California
Government
Eligibility
Not listed
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 23, 2026, 5:28 PM EDT
Recruiting Phase 3 Interventional

Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT 2

NCT04678154
View directory record Official record
Conditions
Post Operative Surgical Site Infection
Interventions
Standard of care, Vancomycin and Tobramycin
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
31
States / cities
Redwood City, California • San Francisco, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 23, 2026, 5:28 PM EDT
Completed Not applicable Interventional

Feedback of Treatment Intensification Data to Reduce Cardiovascular Disease Risk (FIT)

NCT00517686
View directory record Official record
Conditions
Cardiovascular Disease (CVD) Risk Factors
Interventions
Information feedback intervention
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
Not listed
Enrollment
16,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Sep 23, 2026, 5:28 PM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers

NCT03139370
View directory record Official record
Conditions
Solid Tumor
Interventions
KITE-718, Cyclophosphamide, Fludarabine, MAGE - A3/A6 Screening Test
Drug · Device
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
12
States / cities
Gilbert, Arizona • Los Angeles, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 23, 2026, 5:28 PM EDT
Recruiting Phase 3 Interventional

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

NCT07097142
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Survey Administration, Ultrahypofractionated Radiation Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
211
States / cities
Fort Smith, Arkansas • Irvine, California • La Jolla, California + 162 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 23, 2026, 5:28 PM EDT